|
May 22
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
May 7
|
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
|
|
May 6
|
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
|
|
Apr 17
|
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?
|
|
Mar 27
|
High Growth Tech Stocks In The US Market With Promising Potential
|
|
Mar 11
|
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
|
|
Mar 10
|
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
|
|
Feb 17
|
High Growth Tech Stocks In The United States To Watch
|
|
Feb 10
|
Capricor Therapeutics to Participate in Upcoming Investor Conferences
|
|
Jan 3
|
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
|
|
Jan 2
|
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
|
|
Oct 4
|
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
|
|
Oct 3
|
Is Capricor Therapeutics, Inc. (CAPR) the Best Russell 2000 Stock to Buy According to Analysts?
|
|
Sep 26
|
High Growth Tech Stocks To Watch In September 2024
|
|
Jul 31
|
Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7
|
|
Jun 25
|
CORRECTION: Capricor Therapeutics
|
|
Jun 25
|
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
|
|
Jun 4
|
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
|
|
May 14
|
Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 13
|
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
|